Xuebin Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuebin Liao has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
Lu Hu
School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Beijing Advanced Innovation Center for Human Brain Protection, Tsinghua University, Beijing 100084, China
8 shared publications- Yahu A. Liu
Kura Oncology, Inc., San Diego, California
7 shared publications - Hui Chen
Tsinghua University
6 shared publications Licheng Yao
6 shared publicationsWenzhi Ji
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
6 shared publicationsHui Chen
School of Pharmaceutical Sciences, State Key Laboratory of Molecular Oncology, Tsinghua-Peking Center for Life Science, Tsinghua University, Beijing 100084, China
5 shared publications
Latest Publications
- Open Access
- 22 August 2026
- Published by Elsevier in Cell Reports Physical Science
- Vol. 7 (9)
Nickel-catalyzed enantioselective reductive vinyl-alkynylation of unactivated alkenes with bromoalkynes
- 22 August 2026
- Published by Elsevier in Cell Reports Physical Science
- Vol. 7 (9)
Open AccessNickel-catalyzed enantioselective reductive vinyl-alkynylation of unactivated alkenes with bromoalkynes
- Open Access
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
MAP4K1 Disruption Promotes Memory Differentiation Potential in CD8⁺ T Cells and Enhances CAR-T Cell Activity in a First-In-Human B-ALL Trial
HPK1 (MAP4K1) is a hematopoietic kinase that negatively regulates T cell signaling; its deletion in mouse T cells enhances cytotoxicity and anti-tumor activity. Here, we show that MAP4K1 disruption promotes CD8⁺ T cell memory differentiation via mTOR-dependent mitophagy and enhances CAR-T activity in a first-in-human B-ALL trial. Paired scRNA-seq of XYF19 (MAP4K1-disrupted) versus wild-type CD19 CAR-T products from three patients confirmed known transcriptomic changes and revealed increased memory potential. Map4k1 deletion in mouse CD8⁺ T cells recapitulated this after LCMV infection, with increased mitophagy and mitochondrial respiration alongside reduced mTOR/S6/AKT phosphorylation. Map4k1-deficient central memory CD8⁺ T cells suppressed B16-OVA tumors upon adoptive transfer. Clinically, XYF19 showed no grade ≥3 CRS/ICANS and achieved CR/CRi in 11/12 evaluable adults with relapsed/refractory B-ALL. Thus, HPK1 is a kinase regulator of CD8⁺ T cell memory, informing rational engineering and mTOR-mitophagy targeting for durable immunity.
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMAP4K1 Disruption Promotes Memory Differentiation Potential in CD8⁺ T Cells and Enhances CAR-T Cell Activity in a First-In-Human B-ALL Trial
HPK1 (MAP4K1) is a hematopoietic kinase that negatively regulates T cell signaling; its deletion in mouse T cells enhances cytotoxicity and anti-tumor activity. Here, we show that MAP4K1 disruption promotes CD8⁺ T cell memory differentiation via mTOR-dependent mitophagy and enhances CAR-T activity in a first-in-human B-ALL trial. Paired scRNA-seq of XYF19 (MAP4K1-disrupted) versus wild-type CD19 CAR-T products from three patients confirmed known transcriptomic changes and revealed increased memory potential. Map4k1 deletion in mouse CD8⁺ T cells recapitulated this after LCMV infection, with increased mitophagy and mitochondrial respiration alongside reduced mTOR/S6/AKT phosphorylation. Map4k1-deficient central memory CD8⁺ T cells suppressed B16-OVA tumors upon adoptive transfer. Clinically, XYF19 showed no grade ≥3 CRS/ICANS and achieved CR/CRi in 11/12 evaluable adults with relapsed/refractory B-ALL. Thus, HPK1 is a kinase regulator of CD8⁺ T cell memory, informing rational engineering and mTOR-mitophagy targeting for durable immunity.
- 25 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5405-5424
Rational Design and Identification of Highly Selective TLR8 Agonists as Potent HIV-1 Latency Reversal Agents
Highly active antiretroviral therapy (HAART) for HIV-1 infection suppresses but does not cure the disease due to persistent latent viral reservoirs. The "shock and kill" strategy aims to eradicate these reservoirs completely. In exploring the role of TLR8 activation in this context, extensive efforts have been devoted to identify compound 23a, a potent and selective TLR8 agonist with strong agonistic activity (EC50 = 19 nM) and high selectivity (∼1300-fold) over TLR7. Notably, compound 23a exhibits potent reactivation of latent HIV-1 reservoirs in both infected cell lines and primary PBMCs from HAART-treated patients, demonstrating superior efficacy compared to the TLR7 agonist GS-9620 (NCT05281510). Additionally, 23a (SV-128) effectively activated innate cytolytic effectors, including natural killer (NK) cells, which targeted HIV-infected CD4+ T cells. These findings demonstrate the promising therapeutic potential of TLR8 agonists for HIV-1 eradication, combining both "shock" (latency reversal) and "kill" (immune-mediated clearance) mechanisms.
- 25 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5405-5424
Rational Design and Identification of Highly Selective TLR8 Agonists as Potent HIV-1 Latency Reversal Agents
Highly active antiretroviral therapy (HAART) for HIV-1 infection suppresses but does not cure the disease due to persistent latent viral reservoirs. The "shock and kill" strategy aims to eradicate these reservoirs completely. In exploring the role of TLR8 activation in this context, extensive efforts have been devoted to identify compound 23a, a potent and selective TLR8 agonist with strong agonistic activity (EC50 = 19 nM) and high selectivity (∼1300-fold) over TLR7. Notably, compound 23a exhibits potent reactivation of latent HIV-1 reservoirs in both infected cell lines and primary PBMCs from HAART-treated patients, demonstrating superior efficacy compared to the TLR7 agonist GS-9620 (NCT05281510). Additionally, 23a (SV-128) effectively activated innate cytolytic effectors, including natural killer (NK) cells, which targeted HIV-infected CD4+ T cells. These findings demonstrate the promising therapeutic potential of TLR8 agonists for HIV-1 eradication, combining both "shock" (latency reversal) and "kill" (immune-mediated clearance) mechanisms.
- Open Access
Enhance Memory CD8 + T Cell Formation via Downregulation of Hematopoietic Progenitor Kinase 1 and Sustained Mitochondrial Fitness
Memory CD8 + T cells are pivotal for long-term anti-tumor immunity due to their longevity and rapid response upon encountering tumor cells. Hematopoietic progenitor kinase 1 (HPK1), a member of the Ste20 family of kinases, restricts proximal T cell receptor (TCR) signaling and plays critical roles in T cell priming and activation. However, the impact of HPK1 on CD8 + T cell differentiation is not well understood. Here, we demonstrate that chimeric antigen receptor (CAR) T cells derived from patients lacking HPK1 exhibit a stronger memory phenotype. HPK1 deletion promotes the formation of precursor and central memory CD8 + T cells, resulting in superior and long-lasting antitumor activity in murine cancer models compared to WT mice. Additionally, HPK1 knockout induces metabolic reprogramming by enhancing oxidative phosphorylation (OXPHOS) and mitochondrial respiration complex activity. Mechanistically, HPK1 deletion downregulates mTOR signaling by reducing the phosphorylation of mTOR and S6. Increased mitophagy activity is observed in HPK1-depleted cells, with upregulation of key mitophagy regulators, including Pink1 and Bnip3l, maintaining mitochondrial fitness. Our study reveals that HPK1 regulates CD8 + T cell metabolic reprogramming, guiding cell differentiation and antitumor responses.
Open AccessEnhance Memory CD8 + T Cell Formation via Downregulation of Hematopoietic Progenitor Kinase 1 and Sustained Mitochondrial Fitness
Memory CD8 + T cells are pivotal for long-term anti-tumor immunity due to their longevity and rapid response upon encountering tumor cells. Hematopoietic progenitor kinase 1 (HPK1), a member of the Ste20 family of kinases, restricts proximal T cell receptor (TCR) signaling and plays critical roles in T cell priming and activation. However, the impact of HPK1 on CD8 + T cell differentiation is not well understood. Here, we demonstrate that chimeric antigen receptor (CAR) T cells derived from patients lacking HPK1 exhibit a stronger memory phenotype. HPK1 deletion promotes the formation of precursor and central memory CD8 + T cells, resulting in superior and long-lasting antitumor activity in murine cancer models compared to WT mice. Additionally, HPK1 knockout induces metabolic reprogramming by enhancing oxidative phosphorylation (OXPHOS) and mitochondrial respiration complex activity. Mechanistically, HPK1 deletion downregulates mTOR signaling by reducing the phosphorylation of mTOR and S6. Increased mitophagy activity is observed in HPK1-depleted cells, with upregulation of key mitophagy regulators, including Pink1 and Bnip3l, maintaining mitochondrial fitness. Our study reveals that HPK1 regulates CD8 + T cell metabolic reprogramming, guiding cell differentiation and antitumor responses.
- 13 March 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 290, 117488
Rational design, optimization, and biological evaluation of novel pyrrolo-pyridone derivatives as potent and orally active Cbl-b inhibitors
- 13 March 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 290, 117488
Rational design, optimization, and biological evaluation of novel pyrrolo-pyridone derivatives as potent and orally active Cbl-b inhibitors
- 30 April 2024
- Published by Elsevier in Chinese Chemical Letters
- Vol. 36 (3)
Nickel-catalyzed decarboxylative difluoromethylation and alkylation of alkenes
- 30 April 2024
- Published by Elsevier in Chinese Chemical Letters
- Vol. 36 (3)
Nickel-catalyzed decarboxylative difluoromethylation and alkylation of alkenes
- 2 April 2024
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 28 (4) , 237-250
Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress
Hematopoietic progenitor kinase 1 (HPK1), a 97-kDa serine/threonine Ste20-related protein kinase, functions as an intracellular negative regulator, primarily in hematopoietic lineage cells, where it regulates T cells, B cells, dendritic cells and other immune cells. Loss of HPK1 kinase activity results in exacerbated cytokine secretion, enhanced T cell signaling, improved viral clearance, and thus increased restraint of tumor growth. These findings highlight HPK1 as a promising target for immuno-oncology treatments, culminating in the advancement of candidate compounds targeting HPK1 to clinical trials by several biotech enterprises. Through searching PubMed, Espacenet-patent search, and clinicaltrials.gov, this review provides a comprehensive analysis of HPK1, encompassing its structure and roles in various downstream signaling pathways, the consequences of constitutive activation of HPK1, and potential therapeutic strategies to treat HPK1-driven malignancies. Moreover, the review outlines the patents issued for small molecule inhibitors and clinical investigations of HPK1. To enhance the success of tumor immunotherapy in clinical trials, it is important to develop protein degraders, allosteric inhibitors, and antibody-drug conjugates based on the crystal structure of HPK1, and to explore combination therapy approaches. Although several challenges remain, development of HPK1 inhibitors display promising in preclinical and clinical studies.
- 2 April 2024
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 28 (4) , 237-250
Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress
Hematopoietic progenitor kinase 1 (HPK1), a 97-kDa serine/threonine Ste20-related protein kinase, functions as an intracellular negative regulator, primarily in hematopoietic lineage cells, where it regulates T cells, B cells, dendritic cells and other immune cells. Loss of HPK1 kinase activity results in exacerbated cytokine secretion, enhanced T cell signaling, improved viral clearance, and thus increased restraint of tumor growth. These findings highlight HPK1 as a promising target for immuno-oncology treatments, culminating in the advancement of candidate compounds targeting HPK1 to clinical trials by several biotech enterprises. Through searching PubMed, Espacenet-patent search, and clinicaltrials.gov, this review provides a comprehensive analysis of HPK1, encompassing its structure and roles in various downstream signaling pathways, the consequences of constitutive activation of HPK1, and potential therapeutic strategies to treat HPK1-driven malignancies. Moreover, the review outlines the patents issued for small molecule inhibitors and clinical investigations of HPK1. To enhance the success of tumor immunotherapy in clinical trials, it is important to develop protein degraders, allosteric inhibitors, and antibody-drug conjugates based on the crystal structure of HPK1, and to explore combination therapy approaches. Although several challenges remain, development of HPK1 inhibitors display promising in preclinical and clinical studies.
- Open Access
- 9 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
Recent development of new immune checkpoint inhibitors has been particularly successfully in cancer treatment, but still the majority patients fail to benefit. Converting resistant tumors to immunotherapy sensitive will provide a significant improvement in patient outcome. Here we identify Mi-2β as a key melanoma-intrinsic effector regulating the adaptive anti-tumor immune response. Studies in genetically engineered mouse melanoma models indicate that loss of Mi-2β rescues the immune response to immunotherapy in vivo. Mechanistically, ATAC-seq analysis shows that Mi-2β controls the accessibility of IFN-γ-stimulated genes (ISGs). Mi-2β binds to EZH2 and promotes K510 methylation of EZH2, subsequently activating the trimethylation of H3K27 to inhibit the transcription of ISGs. Finally, we develop an Mi-2β-targeted inhibitor, Z36-MP5, which reduces Mi-2β ATPase activity and reactivates ISG transcription. Consequently, Z36-MP5 induces a response to immune checkpoint inhibitors in otherwise resistant melanoma models. Our work provides a potential therapeutic strategy to convert immunotherapy resistant melanomas to sensitive ones.
- 9 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Open AccessMi-2β promotes immune evasion in melanoma by activating EZH2 methylation
Recent development of new immune checkpoint inhibitors has been particularly successfully in cancer treatment, but still the majority patients fail to benefit. Converting resistant tumors to immunotherapy sensitive will provide a significant improvement in patient outcome. Here we identify Mi-2β as a key melanoma-intrinsic effector regulating the adaptive anti-tumor immune response. Studies in genetically engineered mouse melanoma models indicate that loss of Mi-2β rescues the immune response to immunotherapy in vivo. Mechanistically, ATAC-seq analysis shows that Mi-2β controls the accessibility of IFN-γ-stimulated genes (ISGs). Mi-2β binds to EZH2 and promotes K510 methylation of EZH2, subsequently activating the trimethylation of H3K27 to inhibit the transcription of ISGs. Finally, we develop an Mi-2β-targeted inhibitor, Z36-MP5, which reduces Mi-2β ATPase activity and reactivates ISG transcription. Consequently, Z36-MP5 induces a response to immune checkpoint inhibitors in otherwise resistant melanoma models. Our work provides a potential therapeutic strategy to convert immunotherapy resistant melanomas to sensitive ones.
- Open Access
- 16 February 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (1) , 102900
Protocol for Sonogashira coupling of alkynes and aryl halides via nickel catalysis
- 16 February 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (1) , 102900
Open AccessProtocol for Sonogashira coupling of alkynes and aryl halides via nickel catalysis